Progress toward the development of a bacterial vaccine vector that induces high-titer long-lived broadly neutralizing antibodies against HIV-1.
Conformationally constrained HIV-1 Env and gp120 immunogens induce broadly cross-reactive neutralizing antibodies. Thus, it is now feasible to rationally design an HIV-1 vaccine that affords protection through humoral mechanisms. This paper reviews our progress toward the development of an oral bacterial vaccine vector that is capable of delivering an HIV-1 DNA vaccine to host lymphoid tissues and inducing broadly neutralizing antibodies to HIV-1 in the mucosal and systemic immune compartments.
Fouts
T R
TR
Division of Vaccine Research, Institute of Human Virology, 725 W. Lombard Street, Baltimore, MD 21201, USA.
DeVico
A L
AL
Onyabe
D Y
DY
Shata
M T
MT
Bagley
K C
KC
Lewis
G K
GK
Hone
D M
DM
D016915:AIDS Vaccines / Q000276:immunology*; D000284:Administration, Oral; D000818:Animals; D001428:Bacterial Vaccines / Q000235:genetics / Q000276:immunology*; D005260:Female; D015686:Gene Products, env / Q000235:genetics / Q000276:immunology*; D005822:Genetic Vectors; D015483:HIV Antibodies / Q000097:blood* / Q000276:immunology; D015699:HIV Envelope Protein gp120 / Q000235:genetics / Q000276:immunology*; D015497:HIV-1 / Q000276:immunology; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D009500:Neutralization Tests; D012475:Salmonella / Q000235:genetics / Q000276:immunology; D012760:Shigella / Q000235:genetics / Q000276:immunology
D016915:AIDS Vaccines; D001428:Bacterial Vaccines; D015686:Gene Products, env; D015483:HIV Antibodies; D015699:HIV Envelope Protein gp120